The GFAP-Cre; KrasG12D; APCL/+; p53L/L mouse model proves to be a valuable in vivo platform for further research, offering potential biomarkers for early diagnosis and serving as a preclinical tool for the development of innovative GBM therapies. Here, GFAP is linked to glioblastoma.